Phase 3 Gene Therapy for Painful Diabetic Neuropathy

PHASE3CompletedINTERVENTIONAL
Enrollment

507

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Painful Diabetic NeuropathyDiabetic Neuropathy, Painful
Interventions
BIOLOGICAL

Engensis (VM202)

gene therapy

OTHER

placebo

Trial Locations (25)

10032

Columbia University Medical Center Department of Neurology, New York

17402

Martin Foot and Ankle, York

23510

EVMS (Eastern Virginia Medical School), Norfolk

27607

Raleigh Neurology Associates, P.A., Raleigh

32207

UF Health College of Med, Jacksonville, Jacksonville

32611

University of Florida McKnight Brain Institute, Gainesville

32806

Compass Research, LLC, Orlando

33603

Clinical Research of West Florida, Tampa

33756

Innovative Research of West Florida, Clearwater

55455

University of Minnesota, Minneapolis

60611

Northwestern University, Chicago

66160

University of Kansas Medical Center Research Institute, Kansas City

72205

Clinical Trials, Inc., Little Rock

77030

Nerve and Muscle Center of Texas, Houston

84132

University of Utah -Neurology, Salt Lake City

85023

Arizona Research Center, Phoenix

90404

Neurological Research Institute, Santa Monica

94115

Center for Clinical Research, San Francisco

94598

Diablo Clinical Research, Inc., Walnut Creek

95032

Richard S. Cherlin, MD, Los Gatos

95821

Northern California Research, Sacramento

98057

Rainier Clinical Research Center, Inc., Renton

98208

Western Washington Medical Group, Everett

06824

Associated Neurologists of Southern Connecticut, PC, Fairfield

02115

The Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Helixmith Co., Ltd.

INDUSTRY

NCT02427464 - Phase 3 Gene Therapy for Painful Diabetic Neuropathy | Biotech Hunter | Biotech Hunter